For information or to make an
appointment, please call:
at Mount Zion, Parnassus or Serramonte
at Mount Zion, Parnassus or Serramonte
The PLUM Trial: New Study of Medication to Treat Fibroids
What is PLUM?
The PLUM study (Pilot of Letrozole to treat Uterine Leiomyoma) is a study of a medication called letrozole to treat uterine fibroids. You may be eligible for the stud if you are:
What is letrozole?
Letrozole is a pill that is used for many different purposes in women’s health including treatment of infertility, endometriosis, and uterine fibroids. Letrozole is a non-hormonal medication called an aromatase inhibitor. Letrozole works by shrinking down fibroid size to improve fibroid-related symptoms. Although letrozole is used to treat some gynecologic conditions, it is approved by the FDA for a different purpose: to treat postmenopausal women with hormone sensitive breast cancer. Therefore, in this study, the use of letrozole in considered investigational (not FDA approved).
Why is this study being done?
Although some gynecologists use letrozole in their clinical practice to treat women with fibroids, there have been very few studies to evaluate the effectiveness of treatment. This goal of this study is to understand how the use of letrozole impacts fibroid-related symptoms and fibroid size.
Can my fibroids be treated with letrozole?
Women who are having symptoms related to fibroids such as heavy bleeding, pelvic pressure, or urinary frequency may be eligible for treatment with letrozole. At your initial visit, you and the gynecologist will discuss your symptoms and your treatment goals, and review the position and size of your fibroids with radiology imaging (pelvic ultrasound and/or MRI). We will also review with you other possible treatment options for your fibroid-related symptoms including nonsurgical and surgical options.
How can I make an appointment for to discuss enrolling in the PLUM study of letrozole?
If you are interested in letrozole treatment for fibroids, please contact our research coordinators at 415-297-3114 or email@example.com.
Visit our ULTRA Study website for complete details.
THE ULTRA STUDY: ULTRA is a study of a new, FDA approved fibroid treatment called radiofrequency ablation (Acessa™) . This procedure uses heat to destroy fibroid tissue during a laparoscopic surgery. Women return home on the same day as the procedure and are back to their normal activities in 5-9 days. The goal of the study is to evaluate how fibroid symptoms change over time after radiofrequency ablation (Acessa™) . If you participate in the ULTRA study, you will receive radiofrequency ablation (Acessa™) and complete questionnaires about your fibroid symptoms and reproductive health. You may be eligible to participate in the study if you:
You can read more about the ULTRA study at http://clinicaltrials.gov/show/NCT01840124
If you are interested in participating in ULTRA, please contact the study coordinator at 415-297-3114 or by e-mail: firstname.lastname@example.org
WE ARE NOT CURRENTLY ENROLLING IN THE FIRSTT study. Details provided for information only.
UCSF is participating with Mayo Clinic and Duke University in a study funded by the National Institutes of Health to compare uterine artery embolization (UAE) (http://coe.ucsf.edu/coe/fibroid/treatments.html#uterine) and MR-guided focused ultrasound (MRgFUS) (http://www.radiology.ucsf.edu/patient-care/sections/ir/MRgFUS) or the treatment of uterine fibroids. This is the first-ever study in the United States which compares MRgFUS to uterine artery embolization.
The study, called Interventions: Reducing Symptoms Today and Tomorrow (FIRSTT) (http://clinicaltrials.gov/ct2/show/NCT00995878?term=Magnetic+Resonance-guided+Focused+Ultrasound&rank=7) will randomly assign 220 women with symptomatic uterine fibroids to be treated with either MRgFUS or UAE.
The study will follow patients for one year to assess differences between the treatments in fibroid symptom relief, absence of side effects, changes in quality of life, and the need for additional fibroid treatment.
Both treatments are approved by the Food and Drug Administration (FDA) for women who do not plan to become pregnant.
You may qualify for the FIRSTT study if you are:
You can read more about this study at: http://clinicaltrials.gov/ct2/show/NCT00995878?term=mrgfus+and+uae&rank=1
Please contact the study coordinator at 415-297-3114 or by e-mail: email@example.com
Thank you for your interest in our research study.